NeOnc Technologies Holdings (NTHI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
14 Aug, 2026Opening remarks and agenda
Meeting called to order at 10:00 A.M. Pacific Time, with key executives and legal representatives present.
Agenda, rules of conduct, proxy materials, and annual report made available on the virtual meeting website.
Record date for voting set as June 15, 2026, with 25,931,865 shares of common stock eligible to vote.
Quorum confirmed, allowing the meeting to proceed with all proposals.
Board and executive committee updates
Election of two Class 1 directors, Victoria Medvec, PhD, and Steven L. Giannotta, MD, for three-year terms recommended by the nominating and governance committee.
Shareholder proposals
Proposal to elect two Class 1 directors for terms ending at the 2029 annual meeting.
Proposal to amend the 2023 equity incentive plan, increasing shares by 1 million and adding annual increases through 2033.
Proposal to ratify CBIZ CPAs, P.C. as independent auditor for fiscal year ending December 31, 2026.
Adjournment proposal included but not presented due to sufficient votes and quorum.
Latest events from NeOnc Technologies Holdings
- Median OS was 26.09 months and PFS6 was 48.9%, with no major toxicities reported.NTHI
Study result - Q2 2026 net loss was $14.2M; major clinical progress and liquidity concerns persist.NTHI
Q2 2026 - Direct listing on Nasdaq for a biotech with early-stage brain cancer drugs and high capital needs.NTHI
Registration filing - Direct listing of CNS-focused biotech with no commercial revenue, ongoing losses, and exclusive IP.NTHI
Registration filing - Biopharma advancing brain cancer therapies faces high clinical, financial, and regulatory risks.NTHI
Registration filing - Direct listing registers 2.1M shares for resale; early-stage pipeline, high risk, and capital needs.NTHI
Registration filing - Biotech with novel brain cancer therapies in clinical trials, high losses, and ongoing financing needs.NTHI
Registration filing - Clinical-stage biotech registers shares for resale amid ongoing losses and dilution risks.NTHI
Registration filing - Q3 net loss surged to $8.6M as clinical progress and new funding offset high expenses.NTHI
Q3 2025